AstraZeneca announced it has dropped early filing plans of its immunotherapy drug, durvalumab, in head and neck cancer.
The decision comes following Merck's similar Keytruda approved for the same condition.
Just weeks ago, U.S. regulators dealt a setback to durvalumab by placing a temporary halt on enrolling new patients with head and neck cancer in clinical trials, following reports of bleeding
AstraZeneca's main goals for durvalumab still lie in helping previously untreated lung cancer patients.
Read the Reuters coverage